Clavel M, Biron P, Chauvin F, Guastalla J P, Rebattu P, el Foudeh M
Centre Léon-Bérard, Lyon, France.
Bull Cancer. 1989;76(1):75-85.
Metastatic breast adenocarcinoma is a very chemosensitive tumor. Polychemotherapy (CT) is more active than mono-CT inducing a 50-60% response rate in naive chemotherapy patients. The response rate is increased by adding hormonotherapy (HT) to CT in hormone-receptors positive patients. Whether or not HT and CT should be concomitant or consecutive is still questionable. The overall survival remains poor (22-30 months) and no improvement happened during the last decades. A hope for the future is possible from 2 different concepts: high dose chemotherapy or intermittent CT with successive short inductions treatment and no maintenance therapy.
转移性乳腺腺癌是一种对化疗非常敏感的肿瘤。多药化疗（CT）比单药CT更有效，在初治化疗患者中诱导出50-60%的缓解率。在激素受体阳性患者中，在CT基础上加用激素治疗（HT）可提高缓解率。HT和CT应同时使用还是序贯使用仍存在疑问。总体生存率仍然很低（22-30个月），在过去几十年中没有改善。未来的希望可能来自两个不同的概念：高剂量化疗或间歇性CT联合连续短疗程诱导治疗且不进行维持治疗。
